Other reports
CEO To our shareholders

To our shareholders

We remain firmly positioned to return to growth in 2024 and generate long-term, sustainable value for our owners, shareholders, customers, patients, employees, and society.

Belén Garijo Chair of the Executive Board and CEO
read now

Key figures

Net sales
 

20,993 million

Income Statement

EBITDA pre
 

5,879 million

In figures

Earnings per share pre
 

6.49

Shares

Operating
cash flow

3,784 million

Group

Women in
leadership positions

39 %

Diversity and inclusion

Greenhouse gas emissions
(Scope 1 and 2)

-17 %

Climate action